AAM Speaks Out Against Build Back Better Bill
US Pricing Policy Could Unfairly Penalize Generics And Biosimilars Manufacturers
Executive Summary
The US Association for Accessible Medicines has panned the Biden administration’s Build Back Better Act, which it says threatens patient access to affordable drugs in its current form.
You may also be interested in...
Manchin Pushback Bad News For Biden But Good News For Biosimilars
Joe Manchin’s refusal to vote in favor of the Biden administration’s Build Back Better legislation could prove to be a boon for the US biosimilars industry, following weeks of condemnation from the Association for Accessible Medicines.
Rebate Reprieve For Generics And Biosimilars Added To Build Back Better Act
The Build Back Better Act has been updated to exempt generics experiencing or at risk of shortage from its planned inflation rebates, as well as biosimilars. But the US Association for Accessible Medicines has called for further changes to the proposed bill to protect off-patent drugs.
AAM Blasts Build Back Better But Bernstein Offers Balance
Biosimilars could be affected significantly by Build Back Better’s drug price negotiations provision, but industry associations and analysts differ on just how much.